NCT04014257 - A Phase 1 Study of NOV1601(CHC2014) in Adult Subjects With Solid Organ Malignancies | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 9, 2019

Primary Completion Date

January 22, 2021

Study Completion Date

January 29, 2021

Conditions

Phase 1Solid Tumor, Adult

Interventions

DRUG

NOV1601(CHC2014)

a highly selective pan-TRK(tropomyosin receptor kinase) inhibitor targeting tropomyosin receptor kinase A (TRKA), tropomyosin receptor kinase B(TRKB), and tropomyosin receptor kinase C(TRKC)

Trial Locations (4)

Unknown

National Cancer Center, Goyang-si

CHA Bundang Medical Center, Seongnam-si

Seoul National University Hospital, Seoul

Severance Hospital, Seoul